Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $326,975 | $363,095 | $233,977 | $102,083 |
| - Cash | $71,367 | $68,802 | $98,959 | $117,433 |
| + Debt | $43,726 | $20,293 | $23,126 | $44,179 |
| Enterprise Value | $299,334 | $314,586 | $158,144 | $28,829 |
| Revenue | $80,001 | $250,008 | $40,907 | $37,415 |
| % Growth | -68% | 511.2% | 9.3% | – |
| Gross Profit | $80,001 | $157,836 | -$14,857 | -$36,372 |
| % Margin | 100% | 63.1% | -36.3% | -97.2% |
| EBITDA | -$78,556 | $126,455 | -$39,646 | -$68,453 |
| % Margin | -98.2% | 50.6% | -96.9% | -183% |
| Net Income | -$65,002 | $132,330 | -$46,408 | -$71,197 |
| % Margin | -81.3% | 52.9% | -113.4% | -190.3% |
| EPS Diluted | -1.13 | 2.97 | -1.21 | -1.75 |
| % Growth | -138% | 345.5% | 30.9% | – |
| Operating Cash Flow | -$15,310 | $77,919 | -$12,509 | -$53,525 |
| Capital Expenditures | -$3,521 | -$3,256 | -$2,491 | -$1,609 |
| Free Cash Flow | -$18,831 | $74,663 | -$15,000 | -$55,134 |